Courage Therapeutics

About Courage Therapeutics

Courage Therapeutics is a leading neuroendocrine company focused on leveraging the hypothalamus to achieve metabolic homeostasis. Co-founded by Dr. Roger Cone, a pioneer in melanocortin receptor biology, the company aims to translate decades of research into novel therapeutic candidates targeting MC4R and MC3R receptors for treating obesity and eating disorders.

Products & Services

MC4R Programs:Focused on treating genetic and dietary obesity, with compounds showing profound monotherapy activity and synergy with GLP-1 drugs to enhance weight loss, preserve muscle mass, and delay weight regain.

MC3R Programs:Aimed at stimulating food intake for conditions like sarcopenia, anorexia, and cachexia, with potential applications in various eating disorders by reducing anxiety.

Specialties

Neuroendocrine Research Melanocortin Receptor Biology (MC4R and MC3R) Obesity Treatment Eating Disorders Energy Homeostasis

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 11000000 MR: - FA: over $11 million FAN: 11000000	D: 2025-11-03 FD: 2025-11-03	1 investors

Seed Latest

2025-11-03

$11.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Roger Cone

Co-Founder

G

Giovanni Ferrara

CEO

T

Tomi Sawyer

Chief Med-chem

S

Sasha Blaug

CBO-CFO

G

George Grass

Head of Non-Clinical

I

Issac Barchas

GP Arsenal Bridge Ventures

View 7 more team members with Pro

Unlock Full Team Directory

Recent News